Overexpression of CUGBP1 in skeletal muscle from adult classic myotonic dystrophy type 1 but not from myotonic dystrophy type 2. 2013

Rosanna Cardani, and Enrico Bugiardini, and Laura V Renna, and Giulia Rossi, and Graziano Colombo, and Rea Valaperta, and Giuseppe Novelli, and Annalisa Botta, and Giovanni Meola
Laboratory of Muscle Histopathology and Molecular Biology, IRCCS-Policlinico San Donato, Milan, Italy.

Myotonic dystrophy type 1 (DM1) and type 2 (DM2) are progressive multisystemic disorders caused by similar mutations at two different genetic loci. The common key feature of DM pathogenesis is nuclear accumulation of mutant RNA which causes aberrant alternative splicing of specific pre-mRNAs by altering the functions of two RNA binding proteins, MBNL1 and CUGBP1. However, DM1 and DM2 show disease-specific features that make them clearly separate diseases suggesting that other cellular and molecular pathways may be involved. In this study we have analysed the histopathological, and biomolecular features of skeletal muscle biopsies from DM1 and DM2 patients in relation to presenting phenotypes to better define the molecular pathogenesis. Particularly, the expression of CUGBP1 protein has been examined to clarify if this factor may act as modifier of disease-specific manifestations in DM. The results indicate that the splicing and muscle pathological alterations observed are related to the clinical phenotype both in DM1 and in DM2 and that CUGBP1 seems to play a role in classic DM1 but not in DM2. In conclusion, our results indicate that multisystemic disease spectrum of DM pathologies may not be explained only by spliceopathy thus confirming that the molecular pathomechanism of DM is more complex than that actually suggested.

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009223 Myotonic Dystrophy Neuromuscular disorder characterized by PROGRESSIVE MUSCULAR ATROPHY; MYOTONIA, and various multisystem atrophies. Mild INTELLECTUAL DISABILITY may also occur. Abnormal TRINUCLEOTIDE REPEAT EXPANSION in the 3' UNTRANSLATED REGIONS of DMPK PROTEIN gene is associated with Myotonic Dystrophy 1. DNA REPEAT EXPANSION of zinc finger protein-9 gene intron is associated with Myotonic Dystrophy 2. Dystrophia Myotonica,Myotonic Dystrophy, Congenital,Myotonic Myopathy, Proximal,Steinert Disease,Congenital Myotonic Dystrophy,Dystrophia Myotonica 1,Dystrophia Myotonica 2,Myotonia Atrophica,Myotonia Dystrophica,Myotonic Dystrophy 1,Myotonic Dystrophy 2,PROMM (Proximal Myotonic Myopathy),Proximal Myotonic Myopathy,Ricker Syndrome,Steinert Myotonic Dystrophy,Steinert's Disease,Atrophica, Myotonia,Atrophicas, Myotonia,Congenital Myotonic Dystrophies,Disease, Steinert,Disease, Steinert's,Dystrophia Myotonica 2s,Dystrophia Myotonicas,Dystrophica, Myotonia,Dystrophicas, Myotonia,Dystrophies, Congenital Myotonic,Dystrophies, Myotonic,Dystrophy, Congenital Myotonic,Dystrophy, Myotonic,Dystrophy, Steinert Myotonic,Myopathies, Proximal Myotonic,Myopathy, Proximal Myotonic,Myotonia Atrophicas,Myotonia Dystrophicas,Myotonic Dystrophies,Myotonic Dystrophies, Congenital,Myotonic Dystrophy, Steinert,Myotonic Myopathies, Proximal,Myotonica, Dystrophia,Myotonicas, Dystrophia,PROMMs (Proximal Myotonic Myopathy),Proximal Myotonic Myopathies,Steinerts Disease,Syndrome, Ricker
D010641 Phenotype The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment. Phenotypes
D005786 Gene Expression Regulation Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control (induction or repression) of gene action at the level of transcription or translation. Gene Action Regulation,Regulation of Gene Expression,Expression Regulation, Gene,Regulation, Gene Action,Regulation, Gene Expression
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000067879 CELF1 Protein A member of the CELF PROTEINS family which binds GU rich elements (GREs) and CUG-triplet repeats in the 3'UTR of mammalian mRNA transcripts that undergo rapid turnover. It also binds AU-rich elements (AREs or EDEN-like) in the 3'UTR of JUN and FOS mRNAs. Mutations in the human CELF1 gene are associated with MYOTONIC DYSTROPHY type 1. BRUNOL2 Protein,Bruno-Like 2 Protein,CUG Triplet Repeat, RNA-Binding Protein 1,CUGBP, Elav-Like Family Member 1 Protein,CUGBP1 Protein,2 Protein, Bruno-Like,Bruno Like 2 Protein,CUG Triplet Repeat, RNA Binding Protein 1,CUGBP, Elav Like Family Member 1 Protein,Protein, BRUNOL2,Protein, Bruno-Like 2,Protein, CELF1,Protein, CUGBP1
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D012333 RNA, Messenger RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm. Messenger RNA,Messenger RNA, Polyadenylated,Poly(A) Tail,Poly(A)+ RNA,Poly(A)+ mRNA,RNA, Messenger, Polyadenylated,RNA, Polyadenylated,mRNA,mRNA, Non-Polyadenylated,mRNA, Polyadenylated,Non-Polyadenylated mRNA,Poly(A) RNA,Polyadenylated mRNA,Non Polyadenylated mRNA,Polyadenylated Messenger RNA,Polyadenylated RNA,RNA, Polyadenylated Messenger,mRNA, Non Polyadenylated
D016022 Case-Control Studies Comparisons that start with the identification of persons with the disease or outcome of interest and a control (comparison, referent) group without the disease or outcome of interest. The relationship of an attribute is examined by comparing both groups with regard to the frequency or levels of outcome over time. Case-Base Studies,Case-Comparison Studies,Case-Referent Studies,Matched Case-Control Studies,Nested Case-Control Studies,Case Control Studies,Case-Compeer Studies,Case-Referrent Studies,Case Base Studies,Case Comparison Studies,Case Control Study,Case Referent Studies,Case Referrent Studies,Case-Comparison Study,Case-Control Studies, Matched,Case-Control Studies, Nested,Case-Control Study,Case-Control Study, Matched,Case-Control Study, Nested,Case-Referent Study,Case-Referrent Study,Matched Case Control Studies,Matched Case-Control Study,Nested Case Control Studies,Nested Case-Control Study,Studies, Case Control,Studies, Case-Base,Studies, Case-Comparison,Studies, Case-Compeer,Studies, Case-Control,Studies, Case-Referent,Studies, Case-Referrent,Studies, Matched Case-Control,Studies, Nested Case-Control,Study, Case Control,Study, Case-Comparison,Study, Case-Control,Study, Case-Referent,Study, Case-Referrent,Study, Matched Case-Control,Study, Nested Case-Control

Related Publications

Rosanna Cardani, and Enrico Bugiardini, and Laura V Renna, and Giulia Rossi, and Graziano Colombo, and Rea Valaperta, and Giuseppe Novelli, and Annalisa Botta, and Giovanni Meola
September 2010, Human molecular genetics,
Rosanna Cardani, and Enrico Bugiardini, and Laura V Renna, and Giulia Rossi, and Graziano Colombo, and Rea Valaperta, and Giuseppe Novelli, and Annalisa Botta, and Giovanni Meola
January 2019, Frontiers in neurology,
Rosanna Cardani, and Enrico Bugiardini, and Laura V Renna, and Giulia Rossi, and Graziano Colombo, and Rea Valaperta, and Giuseppe Novelli, and Annalisa Botta, and Giovanni Meola
May 2010, Journal of translational medicine,
Rosanna Cardani, and Enrico Bugiardini, and Laura V Renna, and Giulia Rossi, and Graziano Colombo, and Rea Valaperta, and Giuseppe Novelli, and Annalisa Botta, and Giovanni Meola
March 2010, Human molecular genetics,
Rosanna Cardani, and Enrico Bugiardini, and Laura V Renna, and Giulia Rossi, and Graziano Colombo, and Rea Valaperta, and Giuseppe Novelli, and Annalisa Botta, and Giovanni Meola
February 2017, European journal of neurology,
Rosanna Cardani, and Enrico Bugiardini, and Laura V Renna, and Giulia Rossi, and Graziano Colombo, and Rea Valaperta, and Giuseppe Novelli, and Annalisa Botta, and Giovanni Meola
January 2011, The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques,
Rosanna Cardani, and Enrico Bugiardini, and Laura V Renna, and Giulia Rossi, and Graziano Colombo, and Rea Valaperta, and Giuseppe Novelli, and Annalisa Botta, and Giovanni Meola
April 2021, Biofabrication,
Rosanna Cardani, and Enrico Bugiardini, and Laura V Renna, and Giulia Rossi, and Graziano Colombo, and Rea Valaperta, and Giuseppe Novelli, and Annalisa Botta, and Giovanni Meola
June 2012, Neuromuscular disorders : NMD,
Rosanna Cardani, and Enrico Bugiardini, and Laura V Renna, and Giulia Rossi, and Graziano Colombo, and Rea Valaperta, and Giuseppe Novelli, and Annalisa Botta, and Giovanni Meola
June 2022, Trends in molecular medicine,
Rosanna Cardani, and Enrico Bugiardini, and Laura V Renna, and Giulia Rossi, and Graziano Colombo, and Rea Valaperta, and Giuseppe Novelli, and Annalisa Botta, and Giovanni Meola
April 2020, Neuromuscular disorders : NMD,
Copied contents to your clipboard!